Largest biotech by net assets
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Gilead Sciences leads the 24 biotech ranked by net assets, at TRY 1.15T, ahead of BioNTech (TRY 1.08T) and Biogen (TRY 920.9B). Figures as of 18 Nov 2026, 14:23 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Gilead SciencesTRY 1.15T
- Median
- TRY 101.6B
- Combined market value
- TRY 42.83T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Net assets ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Gilead SciencesGILD · Health Care | TRY 1.15T | TRY 10.65T | TRY 8,587.74 | 1.60% up | 33% up | ||
| 2 | BioNTechBNTX · Health Care | TRY 1.08T | TRY 1.06T | TRY 4,280.25 | 0.47% down | 16% down | ||
| 3 | BiogenBIIB · Health Care | TRY 920.9B | TRY 1.87T | TRY 12,649.60 | 0.34% down | 49% up | ||
| 4 | AmgenAMGN · Health Care | TRY 436.7B | TRY 12.49T | TRY 23,097.53 | 0.95% down | 34% up | ||
| 5 | ModernaMRNA · Health Care | TRY 436.3B | TRY 4.22T | TRY 10,430.79 | 3.93% down | 755% up | ||
| 6 | argenxARGX · Health Care | TRY 369.4B | TRY 3.01T | TRY 47,791.96 | 0.36% down | 4% up | ||
| 7 | QiagenQGEN · Health Care | TRY 190.6B | TRY 518.2B | TRY 2,509.34 | 0.12% down | 12% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | TRY 164.1B | TRY 847.1B | TRY 8,368.84 | 0.37% up | 20% up | ||
| 9 | VaxcytePCVX · Health Care | TRY 135.5B | TRY 474.3B | TRY 2,996.08 | 3.59% down | 22% up | ||
| 10 | ExelixisEXEL · Health Care | TRY 109B | TRY 843.1B | TRY 3,455.07 | 2.09% up | 63% up | ||
| 11 | Bio-TechneTECH · Health Care | TRY 106.3B | TRY 575.5B | TRY 3,663.38 | 0.22% down | 26% up | ||
| 12 | RepligenRGEN · Health Care | TRY 106.2B | TRY 522.9B | TRY 8,180.20 | 0.37% down | 5% up | ||
| 13 | CRISPR TherapeuticsCRSP · Health Care | TRY 96.9B | TRY 196.4B | TRY 2,025.13 | 0.54% down | 21% down | ||
| 14 | Revolution MedicinesRVMD · Health Care | TRY 82.3B | TRY 1.77T | TRY 8,205.92 | 2.50% down | 131% up | ||
| 15 | Kymera TherapeuticsKYMR · Health Care | TRY 79.7B | TRY 523.3B | TRY 6,129.35 | 3.44% down | 87% up | ||
| 16 | Krystal BiotechKRYS · Health Care | TRY 61.5B | TRY 446.2B | TRY 15,058.56 | 0.22% up | 46% up | ||
| 17 | ImmunovantIMVT · Health Care | TRY 43B | TRY 346.7B | TRY 1,675.08 | 0.21% down | 43% up | ||
| 18 | CG OncologyCGON · Health Care | TRY 38B | TRY 355.6B | TRY 3,981.65 | 6.89% down | 85% up | ||
| 19 | Twist BioscienceTWST · Health Care | TRY 23.9B | TRY 385.2B | TRY 5,649.17 | 6.63% up | 340% up | ||
| 20 | Scholar Rock HoldingSRRK · Health Care | TRY 12.4B | TRY 277.4B | TRY 2,273.79 | 1.21% up | 14% up | ||
| 21 | Adaptive BiotechnologiesADPT · Health Care | TRY 11B | TRY 232.6B | TRY 1,437.01 | 2.22% up | 88% up | ||
| 22 | Kodiak SciencesKOD · Health Care | TRY 7.9B | TRY 319.3B | TRY 4,882.50 | 3.90% down | 396% up | ||
| 23 | Halozyme TherapeuticsHALO · Health Care | TRY 2.5B | TRY 551.9B | TRY 4,840.63 | 0.55% down | 37% up | ||
| 24 | ImmunityBioIBRX · Health Care | -TRY 25.2B | TRY 335.9B | TRY 315.75 | 4.68% up | 193% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Net assets is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 50.4390 TRY).
Questions and answers
Which biotech rank first by net assets?
Gilead Sciences (TRY 1.15T), BioNTech (TRY 1.08T) and Biogen (TRY 920.9B) are the top three of the 24 biotech ranked by net assets as of 18 Nov 2026, 14:23 UTC.
How many biotech are in this ranking?
24 are ranked by net assets.
What are these biotech worth together?
The 24 biotech ranked by net assets have a combined market value of TRY 42.83T as of 18 Nov 2026, 14:23 UTC.
What does ranking by net assets measure?
Shareholders' equity at the end of the latest fiscal year: what the company owns less what it owes. A negative figure means it owes more than it owns.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by net assets”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=net-assets
Underlying data: Yahoo Finance; SEC EDGAR.